Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga™ (ansuvimab-zykl), a licensed treatment for Ebola virus disease (EVD). “Emergent is proud to continue to advance the Ebanga™ development and scale up to its next phase,” said Paul Williams, senior vice president, products business, Emergent. “We look forward to progressing the program with the goal of supplying treatment courses to enable preparedness against the Ebola virus. We believe this important work further d
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $16.00 price target on the stock.MarketBeat
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action LitigationGlobeNewswire
- Amid Steep Rise In Mpox Cases, Vaccination Drive In Africa Becomes More Urgent [Forbes]Forbes
- Bavarian Nordic stock slides on Moderna mpox vaccine study [Seeking Alpha]Seeking Alpha
EBS
Earnings
- 8/6/24 - Miss
EBS
Sec Filings
- 9/17/24 - Form 8-K
- 9/10/24 - Form SC
- 9/3/24 - Form 8-K
- EBS's page on the SEC website